17 research outputs found

    Evidence for light-by-light scattering and searches for axion-like particles in ultraperipheral PbPb collisions at root s(NN)=5.02 TeV

    Get PDF
    Evidence for the light-by-light scattering process, gamma gamma -> gamma gamma, in ultraperipheral PbPb collisions at a centre-of-mass energy per nucleon pair of 5.02 TeV is reported. The analysis is conducted using a data sample corresponding to an integrated luminosity of 390 mu b(-1) recorded by the CMS experiment at the LHC. Light-by-light scattering processes are selected in events with two photons exclusively produced, each with transverse energy E-T(gamma) > 2 GeV, pseudorapidity vertical bar eta(gamma)vertical bar 5 GeV, diphoton transverse momentum p(T)(gamma gamma) gamma gamma) = 120 +/- 46(stat) +/- 28(syst) +/- 12(theo) nb, is consistent with the standard model prediction. The m(gamma gamma) distribution is used to set new exclusion limits on the production of pseudoscalar axion-like particles, via the gamma gamma -> a -> gamma gamma process, in the mass range m(a) = 5-90 GeV. (C) 2019 The Author(s). Published by Elsevier B.V.Peer reviewe

    Effect of Coadministered Lopinavir and Ritonavir (Kaletra) on Tacrolimus Blood Concentration in Liver Transplantation Patients

    Get PDF
    With the advent of highly active antiretroviral therapy (HAART), HIV positivity is no longer a contraindication for liver transplantation. Some of the antiretroviral agents, particularly protease inhibitors (e.g., ritonavir, indinavir, and nelfinavir) have been described as potent inhibitors of the metabolism of certain immunosuppressive drugs. In this article we describe a profound interaction between tacrolimus and Kaletra (Abbott Laboratories, Chicago, IL) (a combination of lopinavir and ritonavir) in 3 liver transplantation patients. Patient 1, who was maintained on a 5 mg twice daily dose of tacrolimus with a trough blood concentration around 10.6 ng/mL, required only 0.5 mg of tacrolimus per week after addition of Kaletra to achieve similar tacrolimus blood concentrations, with a half-life of 10.6 days. In patient 2, the area under the blood concentration versus time curve for tacrolimus increased from 31 ng/mL/h to 301 ng/mL/h after addition of Kaletra, with a corresponding half-life of 20 days. When the patient was subsequently switched to nelfinavir, the half-life decreased to 10.3 days. Patient 3, who was maintained with 4 to 8 mg/d of tacrolimus and a corresponding blood concentration of 10 ng/mL before Kaletra, required a tacrolimus dose of 1 mg/wk and tacrolimus concentrations of 5 ng/mL with Kaletra. In conclusion, a combination of lopinavir and ritonavir led to a much more profound increase in tacrolimus blood concentrations than use of single protease inhibitor, nelfinavir. A tacrolimus dose of less than 1 mg/wk may be sufficient to maintain adequate blood tacrolimus concentrations in patients on Kaletra. Patients may not need a further dose of tacrolimus for 3 to 5 weeks depending on liver function when therapy with Kaletra is initiated. Great caution is required in the management of tacrolimus dosage when Kaletra is introduced or withdrawn in HIV-positive patients after liver transplantation, particularly in the presence of hepatic dysfunction. (Liver Transpl 2003;9:954-960.

    GI and Liver Transplantation Pathology in Childhood

    No full text

    Rice Improvement Through Genome-Based Functional Analysis and Molecular Breeding in India

    No full text

    Search for dijet resonances using events with three jets in proton-proton collisions at 1as=13 TeV

    No full text

    Measurement of the azimuthal anisotropy of Y(1S) and Y(2S) mesons in PbPb collisions at root s(NN)=5.02 TeV

    No full text

    Search for Higgs and Z boson decays to J/psi or Y pairs in the four-muon final state in proton-proton collisions at root s=13 TeV<bold> </bold>

    No full text
    A search for decays of the Higgs and Z boson to pairs of J/psi or Y(nS)(n = 1, 2, 3) mesons, with their subsequent decay to mu(+)mu(-) pairs, is presented. The analysis uses data from proton-proton collisions at root s = 13 TeV, collected with the CMS detector at the LHC in 2017 and corresponding to an integrated luminosity of 37.5 fb(-1). While an observation of such a decay with this sample would indicate the presence of physics beyond the standard model, no significant excess is observed. Upper limits at 95% confidence level are placed on the branching fractions of these decays. In the J/psi pair channel, the limits are 1.8 x 10(-3) and 2.2 x 10(-6) for the Higgs and Z boson, respectively, while in the combined Y(nS) pair channel, the limits are 1.4 x 10(-3) and 1.5 x 10(-6), respectively, when the mesons from the Higgs and Z boson decay are assumed to be unpolarized. When fully longitudinal and transverse polarizations are considered the limits reduce by about 22-29% and increase by about 10-13%, respectively. (C) 2019 The Author(s). Published by Elsevier B.V

    Search for long-lived particles using nonprompt jets and missing transverse momentum with proton-proton collisions at root s=13 TeV

    No full text
    A search for long-lived particles decaying to displaced, nonprompt jets and missing transverse momentum is presented. The data sample corresponds to an integrated luminosity of 137 fb(-1) of proton-proton collisions at a center-of-mass energy of 13 TeV collected by the CMS experiment at the CERN LHC in 2016-2018. Candidate signal events containing nonprompt jets are identified using the timing capabilities of the CMS electromagnetic calorimeter. The results of the search are consistent with the background prediction and are interpreted using a gauge-mediated supersymmetry breaking reference model with a gluino next-to-lightest supersymmetric particle. In this model, gluino masses up to 2100, 2500, and 1900 GeV are excluded at 95% confidence level for proper decay lengths of 0.3, 1, and 100 m, respectively. These are the best limits to date for such massive gluinos with proper decay lengths greater than similar to 0.5 m. (C) 2019 The Author. Published by Elsevier B.V
    corecore